203 related articles for article (PubMed ID: 15869048)
1. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Naccarelli GV; Lukas MA
Clin Cardiol; 2005 Apr; 28(4):165-73. PubMed ID: 15869048
[TBL] [Abstract][Full Text] [Related]
2. THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Tsetskhladze E; Khintibidze I
Georgian Med News; 2017 Jun; (267):53-57. PubMed ID: 28726654
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?
El-Sherif N; Turitto G
Pacing Clin Electrophysiol; 2005 Sep; 28(9):985-90. PubMed ID: 16176541
[TBL] [Abstract][Full Text] [Related]
4. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Otterstad JE; Ford I
Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
[TBL] [Abstract][Full Text] [Related]
5. A review of carvedilol arrhythmia data in clinical trials.
Kowey PR
J Cardiovasc Pharmacol Ther; 2005 Jun; 10 Suppl 1():S59-68. PubMed ID: 15965573
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
7. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.
Zhou Q; Xiao J; Jiang D; Wang R; Vembaiyan K; Wang A; Smith CD; Xie C; Chen W; Zhang J; Tian X; Jones PP; Zhong X; Guo A; Chen H; Zhang L; Zhu W; Yang D; Li X; Chen J; Gillis AM; Duff HJ; Cheng H; Feldman AM; Song LS; Fill M; Back TG; Chen SR
Nat Med; 2011 Jul; 17(8):1003-9. PubMed ID: 21743453
[TBL] [Abstract][Full Text] [Related]
8. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.
McMurray J; Køber L; Robertson M; Dargie H; Colucci W; Lopez-Sendon J; Remme W; Sharpe DN; Ford I
J Am Coll Cardiol; 2005 Feb; 45(4):525-30. PubMed ID: 15708698
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with carvedilol and amiodarone in patients with severe heart failure.
Nägele H; Bohlmann M; Eck U; Petersen B; Rödiger W
Eur J Heart Fail; 2000 Mar; 2(1):71-9. PubMed ID: 10742706
[TBL] [Abstract][Full Text] [Related]
11. [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Kanopskiĭ SG; Staritskiĭ AG; Bozhko AA
Kardiologiia; 2004; 44(10):13-8. PubMed ID: 15477784
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy.
Kanoupakis EM; Manios EG; Mavrakis HE; Kallergis EM; Lyrarakis GM; Koutalas EP; Vardas PE
Cardiovasc Drugs Ther; 2008 Jun; 22(3):169-76. PubMed ID: 18205033
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group.
Di Lenarda A; Sabbadini G; Salvatore L; Sinagra G; Mestroni L; Pinamonti B; Gregori D; Ciani F; Muzzi A; Klugmann S; Camerini F
J Am Coll Cardiol; 1999 Jun; 33(7):1926-34. PubMed ID: 10362195
[TBL] [Abstract][Full Text] [Related]
14. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
Kopecky SL
Am J Cardiol; 2006 Oct; 98(8):1115-9. PubMed ID: 17027583
[TBL] [Abstract][Full Text] [Related]
15. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol: a review of its use in chronic heart failure.
Keating GM; Jarvis B
Drugs; 2003; 63(16):1697-741. PubMed ID: 12904089
[TBL] [Abstract][Full Text] [Related]
17. Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN).
Fonarow GC; Lukas MA; Robertson M; Colucci WS; Dargie HJ
Am Heart J; 2007 Oct; 154(4):637-44. PubMed ID: 17892984
[TBL] [Abstract][Full Text] [Related]
18. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
Paraskevaidis I; Farmakis D; Parissis JT; Dodouras T; Filippatos G; Tsiapras D; Kremastinos DT
J Card Fail; 2007 Mar; 13(2):108-13. PubMed ID: 17395050
[TBL] [Abstract][Full Text] [Related]
19. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
Joglar JA; Acusta AP; Shusterman NH; Ramaswamy K; Kowal RC; Barbera SJ; Hamdan MH; Page RL
Am Heart J; 2001 Sep; 142(3):498-501. PubMed ID: 11526364
[TBL] [Abstract][Full Text] [Related]
20. New evidence from the CAPRICORN Trial: the role of carvedilol in high-risk, post-myocardial infarction patients.
Sackner-Bernstein JD
Rev Cardiovasc Med; 2003; 4 Suppl 3():S25-9. PubMed ID: 14564231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
